169 related articles for article (PubMed ID: 34330885)
21. Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases.
Kusunoki M; Yanagi H; Noda M; Yoshikawa R; Yamamura T
Cancer; 2000 Sep; 89(6):1228-35. PubMed ID: 11002217
[TBL] [Abstract][Full Text] [Related]
22. Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II study.
Hartmann JT; Köhne CH; Schmoll HJ; Daikeler T; Kanz L; Bokemeyer C
Oncology; 1998; 55(4):320-5. PubMed ID: 9663421
[TBL] [Abstract][Full Text] [Related]
23. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
[TBL] [Abstract][Full Text] [Related]
24. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
[TBL] [Abstract][Full Text] [Related]
25. Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy.
Carlsson G; Odin E; Gustavsson B; Wettergren Y
Cancer Chemother Pharmacol; 2014 Oct; 74(4):757-63. PubMed ID: 25102934
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.
Saif MW; Choma A; Salamone SJ; Chu E
J Natl Cancer Inst; 2009 Nov; 101(22):1543-52. PubMed ID: 19841331
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of infusional biomodulated 5-fluorouracil in metastatic colorectal cancer after raltitrexed failure.
Decoster L; Neyns B; Akouaouach H; Fontaine C; Schallier D; De Grève JL
Anticancer Res; 2004; 24(3b):2037-40. PubMed ID: 15274397
[TBL] [Abstract][Full Text] [Related]
28. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
[TBL] [Abstract][Full Text] [Related]
29. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Falcone A; Di Paolo A; Masi G; Allegrini G; Danesi R; Lencioni M; Pfanner E; Comis S; Del Tacca M; Conte P
J Clin Oncol; 2001 Aug; 19(15):3456-62. PubMed ID: 11481350
[TBL] [Abstract][Full Text] [Related]
30. Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.
Falcone A; Danesi R; Dargenio F; Pfanner E; Brunetti I; Del Tacca M; Nethersell AB; Conte PF
J Clin Oncol; 1996 Mar; 14(3):729-36. PubMed ID: 8622018
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects.
Mindt S; Aida S; Merx K; Müller A; Gutting T; Hedtke M; Neumaier M; Hofheinz RD
Clin Chem Lab Med; 2019 Jun; 57(7):1012-1016. PubMed ID: 30699067
[TBL] [Abstract][Full Text] [Related]
32. Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma.
Martens-Lobenhoffer J; Fuhlroth J; Ridwelski K
Int J Clin Pharmacol Ther; 2000 Jan; 38(1):41-4. PubMed ID: 10667836
[TBL] [Abstract][Full Text] [Related]
33. Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer.
Grim J; Hroch M; Chládek J; Petera J; Martínková J
Clin Pharmacokinet; 2015 May; 54(5):503-15. PubMed ID: 25503423
[TBL] [Abstract][Full Text] [Related]
34. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
[TBL] [Abstract][Full Text] [Related]
35. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
Teh LK; Hamzah S; Hashim H; Bannur Z; Zakaria ZA; Hasbullani Z; Shia JK; Fijeraid H; Md Nor A; Zailani M; Ramasamy P; Ngow H; Sood S; Salleh MZ
Ther Drug Monit; 2013 Oct; 35(5):624-30. PubMed ID: 23942539
[TBL] [Abstract][Full Text] [Related]
36. Second-line treatment with high-dose 5-fluorouracil and folinic acid in advanced colorectal cancer refractory to standard-dose 5-fluorouracil treatment.
Jäger E; Klein O; Wächter B; Müller B; Braun U; Knuth A
Oncology; 1995; 52(6):470-3. PubMed ID: 7478433
[TBL] [Abstract][Full Text] [Related]
37. 5-Fluorouracil Response Prediction and Blood Level-Guided Therapy in Oncology: Existing Evidence Fundamentally Supports Instigation.
Chavani O
Ther Drug Monit; 2020 Oct; 42(5):660-664. PubMed ID: 32649488
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy.
Shiraiwa K; Suzuki Y; Uchida H; Iwashita Y; Tanaka R; Iwao M; Tada K; Hirashita T; Masuda T; Endo Y; Inomata M; Itoh H
Sci Rep; 2021 Feb; 11(1):3132. PubMed ID: 33542452
[TBL] [Abstract][Full Text] [Related]
40. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study.
Hegewisch-Becker S; Gruber Y; Corovic A; Pichlmeier U; Atanackovic D; Nierhaus A; Hossfeld DK
Ann Oncol; 2002 Aug; 13(8):1197-204. PubMed ID: 12181242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
